$VRTX News

Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors

UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585

What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report

Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560

Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada

Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse

Is This Biotech Stock a Buy Near Its 52-Week High?

If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now

Vertex (VRTX) is One of the Best QQQ Stocks to Invest in

IBT portfolio manager: biotech M&A boom set to continue as big pharma hunts

Vertex (VRTX) Stock May Be 36% Undervalued Following Its $10b Deal

Vertex’s Crinetics Deal Balances Growth with Integration Risk

Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside

Vertex Pharmaceuticals (VRTX) Buys Crinetics, Where Does Fair Value Sit Now?

Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal

Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.

Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout

Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note

Vertex (VRTX) Is Buying Crinetics For $10 Billion And Entering Endocrinology